Go to content
UR Home

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

Gratwohl, A. ; Pfirrmann, M. ; Zander, A. ; Kröger, N. ; Beelen, D. ; Novotny, J. ; Nerl, C. ; Scheid, C. ; Spiekermann, K. ; Mayer, J. ; Sayer, H. G. ; Falge, C. ; Bunjes, D. ; Döhner, H. ; Ganser, A. ; Schmidt-Wolf, I. ; Schwerdtfeger, R. ; Baurmann, H. ; Kuse, R. ; Schmitz, N. ; Wehmeier, A. ; Fischer, J. Th. ; Ho, A. D. ; Wilhelm, M. ; Goebeler, M.-E. ; Lindemann, H. W. ; Bormann, M. ; Hertenstein, B. ; Schlimok, G. ; Baerlocher, G. M. ; Aul, C. ; Pfreundschuh, M. ; Fabian, M. ; Staib, P. ; Edinger, M. ; Schatz, M. ; Fauser, A. ; Arnold, R. ; Kindler, T. ; Wulf, G. ; Rosselet, A. ; Hellmann, A. ; Schäfer, E. ; Prümmer, O. ; Schenk, M. ; Hasford, J. ; Heimpel, H. ; Hossfeld, D. K. ; Kolb, H.-J. ; Büsche, G. ; Haferlach, C. ; Schnittger, S. ; Müller, M. C. ; Reiter, A. ; Berger, U. ; Saußele, S. ; Hochhaus, A. ; Hehlmann, R.



Abstract

Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 from 143 centers. Of these, 427 patients were considered eligible for HSCT and were ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons